Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed de novo GBM with documented EGFRvIII expression in tumor tissue.~* Gross total resection followed by conventional chemoradiation therapy without progression of disease.~Exclusion Criteria:~* Presence of diffuse leptomeningeal disease or gliomatosis cerebri.~* Systemic corticosteroid therapy \> 2 mg of dexamethasone or equivalent (as defined by the investigator) per day at study enrollment.~* Patients who have undergone stereotactic radiosurgery prior to or following surgical resection, or the placement of Gliadel® Wafers.~* Known allergy or hypersensitivity to KLH, GM-CSF or yeast derived products, or a history of anaphylactic reactions to shellfish proteins.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CDX-110 with GM-CSF (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).